Results 11 to 20 of about 16,485 (256)

Polyporus umbellatus, A Precious Rare Fungus With Good Pharmaceutical and Food Value. [PDF]

Eng Life Sci
ABSTRACT Polyporus umbellatus is a rare porous fungus that exhibits notable pharmacological activities. Particularly, due to its diuretic properties, it is considered an important source of targeted drugs for the treatment of kidney disease. Extensive research has been conducted on this fungus, focusing not only on its challenging cultivation ...
Ren S, Liu H, Sang Q, Sun Y, Li L, Chen W.   +5 more
europepmc   +2 more sources

Antigen-Targeting Inserted Nanomicelles Guide Pre-Existing Immunity to Kill Head and Neck Cancer. [PDF]

Adv Sci (Weinh)
This study introduces a tumor‐targeted nanomicelle platform (preS1‐pHLIP) that exploits pre‐existing antiviral immunity to combat heterogeneous cancers. By delivering viral antigens to label tumors as virus‐like targets, the nanomicelles activate antiviral B and T cells, triggering in situ tumor lysis.
Zhang L, Feng Q, Zheng C, Li Y, Ge X, Jin T, Hu G, Tan Z, Wang J, Xu J, Jiang L, Wang D, Ying Z, Zhao X, Cheng K, Li Q, Ge M.   +16 more
europepmc   +2 more sources

Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non-Viral CAR-NK Cell Engineering. [PDF]

Cell Prolif
This manuscript provides a comprehensive overview of the state‐of‐the‐art in non‐viral CAR‐NK cell engineering, highlighting its potential to revolutionise cancer treatment. ABSTRACT The recent advancements in cancer immunotherapy have spotlighted the potential of natural killer (NK) cells, particularly chimeric antigen receptor (CAR)–transduced NK ...
Zhou Z, Chen Y, Ba Y, Xu H, Zuo A, Liu S, Zhang Y, Weng S, Ren Y, Luo P, Cheng Q, Zuo L, Zhu S, Zhou X, Zhang C, Chen Y, Han X, Pan T, Liu Z.   +18 more
europepmc   +2 more sources

The Novel Fusion Protein Melittin-MIL-2 Exhibits Strong Antitumor Immune Effect in Lung Adenocarcinoma Cell A549. [PDF]

Clin Respir J
The novel fusion protein melittin‐MIL‐2 may activate immune cells via activating the LFA‐1/ICAM‐1 and Fas/FasL pathways to enhance cytolytic activity, upregulating the production of IFN‐γ and perforin, and boosting LAK‐like and NK‐like killing activities.
Gao W, Li W, Wang Z, Li Y, Liu M.
europepmc   +2 more sources

PBK/TOPK: A Therapeutic Target Worthy of Attention

Cells, 2021
Accumulating evidence supports the role of PDZ-binding kinase (PBK)/T-lymphokine-activated killer-cell-originated protein kinase (TOPK) in mitosis and cell-cycle progression of mitotically active cells, especially proliferative malignant cells.
Ziping Han, Lingzhi Li, Yuyou Huang, Haiping Zhao, Yumin Luo   +4 more
doaj   +1 more source

Influence of Cytokines and Autologous Lymphokine-Activated Killer Cells on Leukemic Bone Marrow Cells and Colonies in AML [PDF]

, 2001
We have already shown that cytokine cocktails (IL-1 beta, IL-3, IL-6, SCF, GM-CSF) and/or lymphokine-activated killer (LAK) cells can reduce the amounts of clonal, CD34-positive mononuclear bone marrow cells (BM-MNC) in acute myeloid leukemia (AML).
Braun, Susanne Walburg, Gerhartz, Helmut Heinrich, Schmetzer, Helga Maria   +2 more
core   +1 more source

The LIN28B–let‐7–PBK pathway is essential for group 3 medulloblastoma tumor growth and survival

Molecular Oncology, 2023
Children with Group 3 medulloblastoma (G3 MB) have a very poor prognosis, and many do not survive beyond 5 years after diagnosis. A factor that may contribute to this is the lack of available targeted therapy.
Shubin W. Shahab, Christianna M. Roggeveen, Jiarong Sun, Haritha Kunhiraman, Leon F. McSwain, Kyle Juraschka, Sachin A. Kumar, Olivier Saulnier, Michael D. Taylor, Matthew Schniederjan, Robert W. Schnepp, Tobey J MacDonald, Anna Marie Kenney   +12 more
doaj   +1 more source

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

Journal for ImmunoTherapy of Cancer, 2022
Background Single-agent immunotherapy has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond.
Reinhard Büttner, Khosro Hekmat, David Kirsch, Michael Hallek, Birgit Gathof, Jana Fassunke, Asmae Gassa, Hakan Alakus, Sven Borchmann, Carolin Selenz, Mia Lohmann, Hanna Ludwig, Johannes Brägelmann, Philipp Lohneis, Lydia Meder, Julia Mattlener, Sara Breid, Marieke Nill, Amy J. Wisdom, Anik Compes, H. Christian Reinhardt, Roland T. Ullrich   +21 more
doaj   +1 more source

Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. [PDF]

, 2019
Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming.
Canter, Robert J, Gingrich, Alicia A, Modiano, Jaime F   +2 more
core   +2 more sources

Present and future of allogeneic natural killer cell therapy

Frontiers in Immunology, 2015
Natural killer (NK) cells are innate lymphocytes that are capable of eliminating tumor cells and are therefore used for cancer therapy. Although many early investigators used autologous NK cells, including lymphokine-activated killer cells, the clinical ...
Okjae eLim, Mi Young eJung, Yu Kyeong eHwang, Eui-Cheol eShin   +3 more
doaj   +1 more source